Please login to the form below

Not currently logged in
Email:
Password:

rare diseases

This page shows the latest rare diseases news and features for those working in and with pharma, biotech and healthcare.

AbbVie calls time on Reata alliance, claims $330m payback

AbbVie calls time on Reata alliance, claims $330m payback

AbbVie has pulled out of a long-running partnership with Reata Pharma on Nrf2 activators for kidney and autoimmune diseases, returning rights to the programmes to the biotech in return for ... AbbVie pulled out of the CKD/DKD partnership but retained opt

Latest news

More from news
Approximately 120 fully matching, plus 251 partially matching documents found.

Latest Intelligence

  • The ‘blueprint’ for MSL success is changing The ‘blueprint’ for MSL success is changing

    rare diseases with complex science and high unmet needs, while treatment decisions are made by multiple stakeholders driven by payers’ demands of economic, societal and cost benefits.

  • Rare diseases: redefining medical communications Rare diseases: redefining medical communications

    Access to treatment. The demonstration of value is key to the successful adoption of treatments for rare diseases. ... Unfortunately, such schemes are often designed to assess treatments for common, rather than rare, diseases.

  • Real-world studies Real-world studies

    myriad of information, from safety monitoring and drug utilisation studies of marketed products in the EU to routine safety monitoring of marketed products and filling evidentiary gaps for particular rare diseases

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    HIV/AIDS and radical patient activists. The most energised and even radical patient activism has tended to occur in rare, life- threatening diseases – the most influential being the HIV/AIDS movement

  • Streamlining clinical trials – why better data use is key Streamlining clinical trials – why better data use is key

    treatments for rare diseases, clinical trial speed and efficiency need to be addressed”.

More from intelligence
Approximately 16 fully matching, plus 85 partially matching documents found.

Latest appointments

  • New faces at imc, GCI Health and Lighthouse US New faces at imc, GCI Health and Lighthouse US

    Additionally, she has also served as a member of the board of management of the ABPI, where she championed access and funding for patients with rare diseases.

  • New faces at Lucid, 90Ten and Page & Page New faces at Lucid, 90Ten and Page & Page

    At Synergy, Bates was project director, working in rare diseases. She was also a publisher at Wounds UK and Wounds international, heading up the medical education division. ... Elaine Downey joins Vivid – Lucid’s rare and specialist diseases agency

  • Weekly industry appointments Weekly industry appointments

    Appleby, who will succeed CGT Catapult’s first CSO Johan Hyllner, currently serves as chief scientific officer for cell and gene therapy at GlaxoSmithKline’s (GSK) rare diseases unit.

  • Paris biocluster appoints Stéphane Roques as new chief Paris biocluster appoints Stéphane Roques as new chief

    He has also chaired the start-up Genosafe and launched the Institute of Biotherapies for Rare Diseases. ... He also chaired the start-up Genosafe and launched the Institute of Biotherapies for Rare Diseases.

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic ... diseases.”.

More from appointments
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 15 fully matching, plus 60 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Infographics